Evolved neural networks for quantitative structure-activity relationships of anti-HIV compounds

Proceedings of the 2002 Congress on Evolutionary Computation, CEC 2002

Volumn 1, Issue , 2002, Pages 199-204

  Landavazo, Dana ^a   Fogel, Gary B ^a  

^a NATURAL SELECTION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER SCIENCE; EVOLUTIONARY ALGORITHMS;

ANTI-HIV COMPOUNDS; DESCRIPTORS; LINEAR MODELING; PREDICTIVE PERFORMANCE; QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP;

NETWORK ARCHITECTURE;

EID: 84901429700     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1109/CEC.2002.1006233     Document Type: Conference Paper

References (37)

1. M. Baba, Z. Debyser, S. Shigeta, E. DeClercq, "Highly potent and selective inhibition of human immunodeficiency virus type 1 (HlV-1) by the HIV-I-specific reverse transcriptase inhibitors," Drugs of the FulureWol 17,pp. 891-897, 1992.
2. M. Baba, H. Tanaka, E. DeClercq, R. Pauwels, J. Balzarini, D. Schols, H. Makashiima, CF. Perno, R.T. Wolker, T. Miyasaka, "Highly specific inhibition of human immunodeficiency viras type 1 by a novel 6-substituted acyclouridine derivative," Biochem. Biophys. Res. Comm. Vol. 165, pp. 1375-1381,1989. (Pubitemid 20029862)
3. E. DeClercq, "Trends in drag development for the treatment of AIDS compounds interfering with the initial stages of the HIV replicative cycle," Eur J. Pharm. Sci. Vol. 2, pp. 4-6, 1994. (Pubitemid 24292103)
4. E. DeClercq "Toward improved anti-HIV chemotherapy: therapeutic shategies for intervention with HIV infections," J. Med. Chem. Vol. 38, pp. 2491-2517, 1995.
5. D.B. Fogel "An information criterion for optimal neural network selection," IEEE Trans. Neural Networks, Vol. 2:5, pp. 490-497, 1991.
6. D.B. Fogel Evolutionary Computation: Toward a New Philosophy of Machine Intelligence, second edition, IEEE Press, Piscataway, NJ, 2000.
7. D.B. Fogel, B.C. Wasson, E.M. Boughton, V.W. Porto, "Evolving neural networks for screening features from mammograms," Artificial Intelligence in Medicine, Vol. 14, pp. 317-326,1998. (Pubitemid 28488718)
8. D.B. Fogel, E.G. Wasson, E.M. Boughton, V.W. Porto, P.J. Angeline, "Linear and Neural Models for Classifying Breast Cancer," IEEE Trans. Medical Imaging, Vol. 17:3, pp. 485-488, 1998. (Pubitemid 128747704)
9. R. Gussio, N. Pattabriaman, G.E. Kellogg, D.W. Zaharevitz, "Use of 3D QSAR methodology for data mining the National Cancer Institute repository of small molecules: applications to HIV-1 Reverse transcriptase inhibition," In METHODS: A companion to Methods in Enzymology, Vol. 14, pp. 255-263, 1998.
10. R. Gussio, N. Pattabiraman, D.W. Zaharevitz, G.E. Kellogg, I.A. Topol, W.G. Rice, CA. Schaefîer, J.W. Erickson, S.K. Burt, "All-atom models for the non-nucleoside binding site of HIV-I reverse transcriptase complexed with inhibitors: a 3D QSAR approach," J. Med Chem. Vol 39, pp. 1645-1650,1996. (Pubitemid 26124237)
11. S. Hannongbua, L. Lawtrakul, J. Limtrakul, "Structure-activity correlation study of HIV-1 inhibitors: electron and molecular parameters," J. Comput.-Aided MoL Design Vol. 10, pp. 145-152, 1996. (Pubitemid 126712811)
12. S. Hannongbua, L. Lawtrakul, CA. Sofrifîer, B.M. Rode, "Comparative molecular field analysis of HIV-1 reverse tratiscriptase inhibitors in the class of l-[(2-hydroxyehtoxy)methyl-6-(phenylthio)- thymine]," Quant. Struct.-Act. Relat Vol. 15, pp. 389-394, (1996)
13. A.L. Hopkins, J. Ren, R.M. Esnouf, B.E. Willcox, E.Y. Jones, C. Ross, T. Miyasaka, R.T. Walker, H. Tanaka, D.K. Stammers, D.I. Smart, "Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors," J. Med. Chem. Vol. 39, pp. 1589-1600, 1996.
14. T.A. Kelly, J.R. Proudfoot, D.W. McNeil, U.R. Patel, E. David, K.D. Hargrave, P.M. Grob, M. Cardozo, A. Agarwal, J. Adams, "Novel non- nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-substituted and 2,4-disubstituted analogs of nevirapine," J. Med. Chem. Vol. 38, pp. 4839-4847, 1995.
15. H. Mitsuya, R. Yarchoan, S. Broder, "Molecular targets for AIDS therapy," Science Vol. 249, pp. 1533-1544, 1990.
16. A. Jacobo-Molina, J. Ding, R.G. Nanni, A.D. Clark, X. Lu, C. Tantillo, R.L. Williams, G. Kamer, A.L. Ferris, P. Clerck, A. Hizi, S. Huges, E. Arnold, "Crystal stracture of the human immunodeficiency viras type I reverse transcriptase complexed with double-stranded DNA at 3.0A resolution shows bent DNA," Proc. Natl Acad. Sci. USA Vol. 90, pp. 6320-6324,1993. (Pubitemid 23191507)
17. D.B. Kireev, J.R. Chretien, D.S. Grierson, C. Monneret, "A 3D QSAR study of a series of HEPT analogous: the influence of conformational mobility on HlV-1 reverse franscriptase inhibition," J Med. Chem. Vol. 40, pp. 4257-1264, 1997.
18. D.G. Landavazo, G.B. Fogel, D.B. Fogel, "Quantitative stmcture- activity relationships by evolved neural networks for the inhibition of dihydrofolate reductase by pyrimidines," BioSystems in press, 2002.
19. J.M. Luco, F.H. Ferretti, "QSAR based on multiple linear regression and PLS methods for the anti-HlV activity of a large group of HEPT derivatives," J. Chem. Inf Comput. Sci. Vol. 37, pp. 392-401, 1997. (Pubitemid 127603544)
20. B.T. Luke, "Evolutionary,programming applied to the development of quantitative stracture-activity relationships and quantitative stracture- property relationships," J. Chem. Inf. Comput. Sci., Vol. 34, pp. 1279- 1287, 1994.
21. V.W. Porto, D.B. Fogel, and L.J. Fogel, "Alternative Neural Network Training Methods," IEEE Expert, June, pp. 16-22, 1995.
22. J.A. Sandberg, W. Slikker, "Development pharmacology and toxicology of anti-HIV therapeutic agents: dideoxynucleosides," FASEBJ. Vol. 9, pp. 1157-1163, 1995.
23. R.F. Schinazi, "Competitive inhibitors of human immunodeficiency viras reverse transcriptase," Perspect Drug Disc. Des. Vol. 1, pp. 151- 180, 1993.
24. S.-S. So and M. Karplus, "Evolutionary optimization in quantitative stracture-activity relationship: an application of genetic neural networks,"y. Med Chem., Vol, 39, pp. 1521-1530, 1996a. (Pubitemid 26108787)
25. S.-S. So and M. Karplus, "Genetic neural networks for quantitative stracture-activity relationships: improvements and application of benzodiazepine affinity for benzodiazepine/GABAA receptors." J. Med. Chem., Vol. 39, pp. 5246-5256, 1996b.
26. S.-S. So and M. Karplus, "Three-dimensional quantitative sfructare- activity relationships from molecular similarity matrices and genetic neural networks. 1. method and validations." J Med. Chem., Vol. 40, pp. 4347-4359, 1997a. (Pubitemid 28042314)
27. S.-S. So and M. Karplus, "Three-dimensional quantitative stracture- activity relationships from molecular similarity matrices and genetic neural networks. 2. applications. J Med. Chem., Vol. 40, pp. 4360- 4371, 1997b.
28. H. Tanaka, H. Takashima, M. Ubasawa, K. Sekiya, 1. Nitta, M. Baba, S. Shigeta, R.T. Walker, E. DeClercq, T. Miyasaka, "Synthesis and Antiviral Activity of Deoxy Analogs of 1-[(2-Hydroxyethoxy)-methyl]- 6-(phenylthio)thymine (HEPT) as Potent and Selective Anti-HIV-1 Agents," J MedChem. Vol. 35,pp.4713-4719,1992. (Pubitemid 23033722)
29. H. Tanaka, H. Takashima, M. Ubasawa, K. Sekiya, I. Nitta, M. Baba, S. Shigeta, R.T. Walker, E. DeClercq, T. Miyasaka, "Stracture-Activity Relationships of l-[(2-Hydrocyethoxy)methyl]-6-(phenylthio)-thymine Analogues: Effect of Substitutions at the C-6 Phenyl Ring and the C-5 Position on Anti-HIV-1 Activity," J. Med. Chem. Vol. 35, pp. 337- 345., 1992.
30. H. Tanaka, M. Baba, H. Hayakawa, K. Haraguchi, T. Miyasaka, M. Ubasawa, H. Takashima, K. Sekiya, I. Nitta, R.T. Walker, E. DeClercq, "Lithiation of Uracilnucleosides and its Application to the Synthesis of a New Class of Anti-HIV-1 Acyclonucleosides," Nucleosides & Nucleotides Vol .10, pp. 397-400,1991.
31. H. Tanaka, M. Baba, S. Saito, T. Miyasaka, H. Takashima, K. Seikya, M. Ubasawa, I. Nitta, R.T. Walker, H. Nakashima, E. DeClercq, " Acyclnucleosides" Which Cannot Be Phosphorylated: Synthesis of Some Deoxy Analogues of 1-[(2-Hydroxyehtoxy)methyl]-6- (phenylthio)thymine," J. Med Chem. Vol. 34, pp. 1508-1511,1991.
32. H. Tanaka, M. Baba, M. Ubasawa, H. Takashima, K. Sekiya, I. Nitta, S. Shigeta, R.T. Walker, E. DeClercq, T. Miyasaka, "Synthesis of Anti- HIV Activity of 2-, 3-, 4-Substituted Analogues of l-[(2- Hydroxyethoxy)methyl]-6- {phenylthio)thymine (HEPT)," J. Med. Chem. Vol. 34, pp. 1394-1399, 1991.
33. H. Tanaka, M. Baba, H. Hayakawa, T. Sakamaki, T. Miyasaka, M. Ubasawa, H. Takashima, K. Sekiya, I. Nitta, S. Shigeta, R.T. Walker, J. Balzarini, E. DeClercq, "A New Class of HIV-I-Specific 6-Substituted Acyclouridine Derivatives: Synthesis and Anti-HIV-1 Activity of 5-, or 6-Substituted Analogues of l-[(2-Hydroxyethocy)-methyl]-6- (phenylthio)thymine (HEPT)," J. Med Chem. Vol. 34, pp. 349-357, 1991.
34. H. Tanaka, M. Baba, M. Ubasawa, H. Takashima, K. Sekiya, T. Miyasaka, T. Nitta, R.T. Walker, E. DeClercq, "The Synthesis of Novel 6-Substituted Acyclouridine Derivatives which Show Specific Inhibition of HIV-1," Collect. Czech. Chem. Commun. Vol. 55, pp. 89- 92, 1990.
35. I.V. Tetko, V.Y. Tanchuk, and A.I. Luik, "Application of an Evolutionary Algorithm to the Structure-Activity Relationship" Proc. of the Third Ann. Conf on Evol. Prog., (A. Sebald and L. Fogel, eds.). World Scientific, New Jersey. 1994: pp.109-118,1994.
36. D.H. Wolpert and W.G. Macready, "No free lunch theorems for optimization," IEEE Trans. Evol. Comput. Vol. 1, pp. 67-82, 1997.
37. X. Yao, "Evolving artificial neural networks," Proc. IEEE Vol. 87, pp. 1423-1447,1999.